Patents by Inventor Mary K. Wloch
Mary K. Wloch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8821890Abstract: The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.Type: GrantFiled: September 30, 2011Date of Patent: September 2, 2014Assignee: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Publication number: 20120128717Abstract: The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.Type: ApplicationFiled: September 30, 2011Publication date: May 24, 2012Applicant: Vical IncorporatedInventors: Catherine J. LUKE, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Patent number: 8128938Abstract: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo.Type: GrantFiled: August 17, 2007Date of Patent: March 6, 2012Assignee: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Publication number: 20120045467Abstract: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo.Type: ApplicationFiled: August 17, 2007Publication date: February 23, 2012Applicant: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Patent number: 7785603Abstract: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo.Type: GrantFiled: March 9, 2007Date of Patent: August 31, 2010Assignee: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Publication number: 20100197771Abstract: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo.Type: ApplicationFiled: January 15, 2010Publication date: August 5, 2010Applicant: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Patent number: 7537768Abstract: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo.Type: GrantFiled: February 9, 2007Date of Patent: May 26, 2009Assignee: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez